Evidence map›Paper›PMID 36396317›Full record

ArticleBMJ open2022

Evaluating the feasibility, effectiveness and costs of implementing person-centred follow-up care for childhood cancer survivors in four European countries: the PanCareFollowUp Care prospective cohort study protocol.

Rebecca J van Kalsbeek, Joke C Korevaar, Mieke Rijken, Riccardo Haupt, Monica Muraca, Tomáš Kepák, Katerina Kepakova, Anne Blondeel, Stefan Boes, Line E Frederiksen and 17 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 15 institutions in 10 countries.

Rebecca J van KalsbeekPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands R.J.vanKalsbeek@prinsesmaximacentrum.nl.ORCID 0000-0003-3407-6508
Joke C KorevaarNetherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands.ORCID 0000-0001-9997-040X
Mieke RijkenNetherlands Institute for Health Services Research (NIVEL), Utrecht, The Netherlands.ORCID 0000-0001-6070-4091
Riccardo HauptDOPO Clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.ORCID 0000-0003-0571-8460
Monica MuracaDOPO Clinic, Department of Hematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.ORCID 0000-0001-5259-7046
Tomáš KepákInternational Clinical Research Centre (FNUSA-ICRC) at St Anne's University Hospital, Masaryk University Faculty of Medicine, Brno, Czech Republic.
Katerina KepakovaInternational Clinical Research Centre (FNUSA-ICRC) at St Anne's University Hospital, Masaryk University Faculty of Medicine, Brno, Czech Republic.
Anne BlondeelEuropean Society for Pediatric Oncology (SIOP Europe), Brussels, Belgium.
Stefan BoesDepartment of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID 0000-0001-5478-9105
Line E FrederiksenChildhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0003-3841-9053
Samira EssiafEuropean Society for Pediatric Oncology (SIOP Europe), Brussels, Belgium.
Jeanette F WintherChildhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0002-3440-5108
Rosella P M G HermensScientific Institute for Quality of Healthcare (IQ Healthcare), Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0001-7624-7120
Anita KienesbergerChildhood Cancer International Europe, Vienna, Austria.
Jacqueline J LoonenDepartment of Hematology, Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0002-9963-8367
Gisela MichelDepartment of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID 0000-0002-9589-0928
Renée L MulderPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-0414-9561
Kylie B O'BrienPintail, Limited, Dublin, Ireland.ORCID 0000-0002-4412-1483
Helena J H van der PalPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0003-2253-2115
Saskia M F PluijmPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-4459-7799
Katharina RoserDepartment of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID 0000-0001-5253-3333
Roderick SkinnerWolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.ORCID 0000-0002-1162-675X
Marleen RenardDepartment of Paediatric Haematology and Oncology, KU Leuven, University Hospitals Leuven, Leuven, Belgium.
Anne UyttebroeckDepartment of Paediatric Haematology and Oncology, KU Leuven, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-5644-424X
Cecilia FollinDepartment of Clinical Sciences Lund, Oncology, Lund University, Skane University Hospital, Lund, Sweden.
Lars HjorthDepartment of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden.ORCID 0000-0002-8302-7174
Leontien C M KremerPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0001-7422-3248
Princess Máxima Center · NLUniversity of Lucerne · CHEuropean Society for Paediatric Oncology · BEIstituto Giannina Gaslini · ITKU Leuven · BELund University · SEMasaryk University · CZRadboud University Nijmegen · NLAarhus University · DKDanish Cancer Society · DKEmma Kinderziekenhuis · NLNetherlands Institute for Health Services Research · NLPintail (Ireland) · IERoyal Victoria Infirmary · GBUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong-term survival after childhood cancer often comes at the expense of late, adverse health conditions. However, survivorship care is frequently not available for adult survivors in Europe. The PanCareFollowUp Consortium therefore developed the PanCareFollowUp Care Intervention, an innovative person-centred survivorship care model based on experiences in the Netherlands. This paper describes the protocol of the prospective cohort study (Care Study) to evaluate the feasibility and the health economic, clinical and patient-reported outcomes of implementing PanCareFollowUp Care as usual care in four European countries. METHODS AND ANALYSIS: In this prospective, longitudinal cohort study with at least 6 months of follow-up, 800 childhood cancer survivors will receive the PanCareFollowUp Care Intervention across four study sites in Belgium, Czech Republic, Italy and Sweden, representing different healthcare systems. The PanCareFollowUp Care Intervention will be evaluated according to the Reach, Effectiveness, Adoption, Implementation and Maintenance framework. Clinical and research data are collected through questionnaires, a clinic visit for multiple medical assessments and a follow-up call. The primary outcome is empowerment, assessed with the Health Education Impact Questionnaire. A central data centre will perform quality checks, data cleaning and data validation, and provide support in data analysis. Multilevel models will be used for repeated outcome measures, with subgroup analysis, for example, by study site, attained age, sex or diagnosis. ETHICS AND DISSEMINATION: This study will be conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. The study protocol has been reviewed and approved by all relevant ethics committees. The evidence and insights gained by this study will be summarised in a Replication Manual, also including the tools required to implement the PanCareFollowUp Care Intervention in other countries. This Replication Manual will become freely available through PanCare and will be disseminated through policy and press releases. TRIAL REGISTRATION NUMBER: Netherlands Trial Register (NL8918; https://www.trialregister.nl/trial/8918).

Indexed as

Cancer SurvivorsNeoplasmsAdultAftercareChildEuropeFeasibility StudiesHumansLongitudinal StudiesProspective StudiesHealth economicsInternational health servicesOrganisation of health servicesPaediatric oncology

Identifiers

PMID36396317
PMCPMC9677022
OpenAlexW4309618216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.